173 related articles for article (PubMed ID: 11329102)
1. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group.
Van der Vring JA; Cleophas TJ; Van der Wall EE; Niemeyer MG
Am J Ther; 1999 Jul; 6(4):229-33. PubMed ID: 11329102
[TBL] [Abstract][Full Text] [Related]
2. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
[TBL] [Abstract][Full Text] [Related]
3. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
4. T-type Ca2+ channel blockade prevents sudden death in mice with heart failure.
Kinoshita H; Kuwahara K; Takano M; Arai Y; Kuwabara Y; Yasuno S; Nakagawa Y; Nakanishi M; Harada M; Fujiwara M; Murakami M; Ueshima K; Nakao K
Circulation; 2009 Sep; 120(9):743-52. PubMed ID: 19687356
[TBL] [Abstract][Full Text] [Related]
5. Effects of the T-type calcium channel blockade with oral mibefradil on the electrophysiologic properties of the human heart.
Mádle A; Linhartová K; Koza J
Med Sci Monit; 2001; 7(1):74-7. PubMed ID: 11208497
[TBL] [Abstract][Full Text] [Related]
6. The T- and L-type calcium channel blocker (CCB) mibefradil attenuates leg edema induced by the L-type CCB nifedipine in the spontaneously hypertensive rat: a novel differentiating assay.
Major TC; Dhamija S; Black N; Liachenko S; Morenko B; Sobocinski G; Okerberg C; Tinholt P; Madore S; Kowala MC
J Pharmacol Exp Ther; 2008 Jun; 325(3):723-31. PubMed ID: 18326812
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2.
Moosmang S; Haider N; Brüderl B; Welling A; Hofmann F
Circ Res; 2006 Jan; 98(1):105-10. PubMed ID: 16306443
[TBL] [Abstract][Full Text] [Related]
8. State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel.
Freeze BS; McNulty MM; Hanck DA
Mol Pharmacol; 2006 Aug; 70(2):718-26. PubMed ID: 16699084
[TBL] [Abstract][Full Text] [Related]
9. Ca2+ channel subtypes and pharmacology in the kidney.
Hayashi K; Wakino S; Sugano N; Ozawa Y; Homma K; Saruta T
Circ Res; 2007 Feb; 100(3):342-53. PubMed ID: 17307972
[TBL] [Abstract][Full Text] [Related]
10. [Calcium antagonists in the treatment of heart failure. Re-evaluation of therapeutic strategies].
Gattis W; O'Connor CM
Drugs; 2000; 59 Spec No 2():17-24. PubMed ID: 11002855
[TBL] [Abstract][Full Text] [Related]
11. Divergent natriuretic action of calcium channel antagonists in mongrel dogs: renal haemodynamics as a determinant of natriuresis.
Honda M; Hayashi K; Matsuda H; Kubota E; Tokuyama H; Okubo K; Ozawa Y; Saruta T
Clin Sci (Lond); 2001 Oct; 101(4):421-7. PubMed ID: 11566080
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial.
Lee DS; Goodman S; Dean DM; Lenis J; Ma P; Gervais PB; Langer A;
Am Heart J; 2002 Jul; 144(1):60-7. PubMed ID: 12094189
[TBL] [Abstract][Full Text] [Related]
13. Sustained-release calcium channel antagonists in cardiovascular disease: pharmacology and current therapeutic use.
Silvestry FE; St John Sutton MG
Eur Heart J; 1998 Aug; 19 Suppl I():I8-14. PubMed ID: 9743438
[TBL] [Abstract][Full Text] [Related]
14. [Mibefradil--a T-type calcium channel blocker].
Roguin A; Edoute Y
Harefuah; 1999 Jan; 136(2):167-9. PubMed ID: 10914190
[No Abstract] [Full Text] [Related]
15. Mibefradil: "Has the baby been thrown out with the bath water?".
Beltrame JF; Turner SP; Leslie S; Horowitz JD
Am Heart J; 2003 Jul; 146(1):e3. PubMed ID: 12851630
[No Abstract] [Full Text] [Related]
16. Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives.
Jo MN; Seo HJ; Kim Y; Seo SH; Rhim H; Cho YS; Cha JH; Koh HY; Choo H; Pae AN
Bioorg Med Chem; 2007 Jan; 15(1):365-73. PubMed ID: 17035033
[TBL] [Abstract][Full Text] [Related]
17. [Molecular effects of new calcium antagonists: is the principle of parcimony out of place?].
Richard S; Virsolvy A; Fort A
Ann Cardiol Angeiol (Paris); 2008 Jun; 57(3):166-73. PubMed ID: 18565491
[TBL] [Abstract][Full Text] [Related]
18. Mibefradil--a new calcium-channel blocker.
Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
[No Abstract] [Full Text] [Related]
19. 3D pharmacophore based virtual screening of T-type calcium channel blockers.
Doddareddy MR; Choo H; Cho YS; Rhim H; Koh HY; Lee JH; Jeong SW; Pae AN
Bioorg Med Chem; 2007 Jan; 15(2):1091-105. PubMed ID: 17074493
[TBL] [Abstract][Full Text] [Related]
20. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
Kuti EL; Baker WL; White CM
Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
